肝动脉栓塞化疗术联合口服替吉奥在结直肠癌肝转移中的疗效评价  

The Analysis of TACE Interventional Therapy Combined with Oral S-1 Tablets for Liver Metastases from Colorectal Carcinoma Efficacy

作　　者：王玉然[1] 张晴晴[2] 高志成[1] 于国秀 代一佳 李贵新[3] 

机构地区：[1]潍坊医学院肿瘤学教研室,山东潍坊261053 [2]潍坊医学院感染病学教研室 [3]潍坊市中医院保健科

出　　处：《潍坊医学院学报》2017年第2期139-141,共3页Acta Academiae Medicinae Weifang

摘　　要：目的评价肝动脉栓塞化疗术联合口服单药替吉奥在大肠癌肝转移中的疗效和安全性。方法将68例大肠癌肝转移患者随机分为两组,观察组32例,给予肝动脉栓塞化疗术联合口服替吉奥,对照组36例,给予肝动脉栓塞化疗术。观察两组患者的治疗效果和不良反应。结果观察组有效率为50.00%,对照组有效率为22.22%(P<0.05),观察组患者12,24,48个月生存率分别为90.63%,75.00%,21.88%,均高于对照组(P<0.05);两组患者治疗后均未出现严重并发症。结论 TACE联合口服替吉奥是治疗结直肠癌肝转移安全、有效的方法,值得临床应用。Objective To investigate the clinical effects and risks of S-1 （ tegafur/gimeracil/oteracil potassium） tablets combined with transcatheter arterial chemoembolization （TACE） interventional therapy for liver metastases from colorectal carcinoma. Methods All 68 patients were divided into two groups according to the treatment method,32 cases were given TACE combined with oral S-1 tablets in the observation group ,36 cases were given transcatheter arterial chemoembolization （TACE） in control group, then compared with the treatment effect and adverse reaction between the two groups. Results The RR rate of the research group was 50.00%, the RR rate in the control group was 22.22% （ P 〈 0. 05 ） ,the patients in study group, 12 months,24 months ,48 months survival rates were 90.63% ,75.00% ,21.88% were higher than the control group （ P 〈 0. 05 ） ; There were no Conclusion Interventional therapy combined with S-1 tablets serious complications in the two groups after treatment. orally was safe and effective for live metastais from colorectal carcinoma.

关 键 词：替吉奥 TACE 结直肠肿瘤 肝转移 疗效 

分 类 号：R735.34[医药卫生—肿瘤]